Literature DB >> 29220797

Primaquine hybrids as promising antimycobacterial and antimalarial agents.

Kristina Pavić1, Ivana Perković1, Šárka Pospíšilová2, Marta Machado3, Diana Fontinha3, Miguel Prudêncio3, Josef Jampilek4, Aidan Coffey5, Lorraine Endersen5, Hrvoje Rimac1, Branka Zorc6.   

Abstract

Four series of primaquine (PQ) derivatives were screened for antitubercular and antiplasmodial activity: amides 1a-k, ureas 2a-s, semicarbazides 3a-c and bis-ureas 4a-u. Antimycobacterial activity of PQ derivatives against Mycobacterium tuberculosis (MTB), M. avium complex (MAC) and M. avium subsp. paratuberculosis (MAP) were evaluated in vitro and compared with PQ and the standard antitubercular drugs. In general, the PQ derivatives showed higher potency than the parent compound. Most of the compounds of series 1 and 2 showed high activity against MAP, comparable or even higher than the relevant drug ciprofloxacin, and weak or no activity against MTB and MAC. bis-Trifluoromethylated cinnamamide 1k showed low cytotoxicity and high activity against all three Mycobacterium species and their activities were comparable or slightly higher than those of the reference drugs. PQ urea derivatives with hydroxyl, halogen and trifluoromethyl substituents on benzene ring 2f-p exerted very strong antimycobacterial activity towards all tested mycobacteria, stronger than PQ and the relevant standard drug(s). Unfortunately, these compounds had relatively high cytotoxicity, except bromo 2l and trifluoromethyl 2m, 2n derivatives. In general, meta-substituted derivatives were more active than analogues para-derivatives. Phenyl ureas were also more active than cycloalkyl or hydroxyalkyl ureas. Semicarbazide 3a showed similar activity as PQ, while the other two semicarbazides were inactive. Bis-urea derivatives 4 were generally less active than the urea derivatives sharing the same scaffold, differing only in the spacer type. Out of 21 evaluated bis-urea derivatives, only p-Cl/m-CF3 phenyl derivative 4p, benzhydryl derivatives 4t and 4u and bis-PQ derivative 4s showed high activity, higher than all three reference drugs. After comparison of activity and cytotoxicity, urea 2m and bis-urea 4u could be considered as the most promising agents. Antimalarial potential of PQ derivatives in vitro against the liver stage of P. berghei was evaluated as well. 3-(4-Chlorophenyl)-1-[({4-[(6-methoxyquinolin-8-yl)amino]pentyl}carbamoyl)amino]urea (4l) was the most active compound (IC50 = 42 nM; cytotoxicity/activity ratio >2000). Our results bring new insights into development of novel anti-TB and antimalarial compounds.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antimycobacterial activity; Antiplasmodial activity; Hybrid; Primaquine

Mesh:

Substances:

Year:  2017        PMID: 29220797     DOI: 10.1016/j.ejmech.2017.11.083

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

Review 1.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

2.  Second generation of primaquine ureas and bis-ureas as potential antimycobacterial agents.

Authors:  Kristina Pavić; Zrinka Rajić; Hana Michnová; Josef Jampílek; Ivana Perković; Branka Zorc
Journal:  Mol Divers       Date:  2018-12-06       Impact factor: 2.943

3.  SAHAquines, Novel Hybrids Based on SAHA and Primaquine Motifs, as Potential Cytostatic and Antiplasmodial Agents.

Authors:  Maja Beus; Zrinka Rajić; Dusica Maysinger; Zvonimir Mlinarić; Maja Antunović; Inga Marijanović; Diana Fontinha; Miguel Prudêncio; Jana Held; Sureyya Olgen; Branka Zorc
Journal:  ChemistryOpen       Date:  2018-08-21       Impact factor: 2.911

4.  Insights into biological activity of ureidoamides with primaquine and amino acid moieties.

Authors:  Josipa Vlainić; Ivan Kosalec; Kristina Pavić; Dimitra Hadjipavlou-Litina; Eleni Pontiki; Branka Zorc
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 5.  Primaquine derivatives: Modifications of the terminal amino group.

Authors:  Branka Zorc; Ivana Perković; Kristina Pavić; Zrinka Rajić; Maja Beus
Journal:  Eur J Med Chem       Date:  2019-08-23       Impact factor: 6.514

6.  Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds.

Authors:  Giorgio Facchetti; Michael S Christodoulou; Lina Barragán Mendoza; Federico Cusinato; Lisa Dalla Via; Isabella Rimoldi
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

7.  Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B.

Authors:  Narayan D Chaurasiya; Haining Liu; Robert J Doerksen; N P Dhammika Nanayakkara; Larry A Walker; Babu L Tekwani
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-22

Review 8.  Quinoline derivatives volunteering against antimicrobial resistance: rational approaches, design strategies, structure activity relationship and mechanistic insights.

Authors:  Nitish Kumar; Aanchal Khanna; Komalpreet Kaur; Harmandeep Kaur; Anchal Sharma; Preet Mohinder Singh Bedi
Journal:  Mol Divers       Date:  2022-10-05       Impact factor: 3.364

9.  Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors.

Authors:  Zrinka Rajić; Maja Beus; Hana Michnová; Josipa Vlainić; Leentje Persoons; Ivan Kosalec; Josef Jampílek; Dominique Schols; Toma Keser; Branka Zorc
Journal:  Molecules       Date:  2018-07-14       Impact factor: 4.411

Review 10.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.